Va pbmmap and center for medication safetys guidance on offlabel prescribing available on the. Health care professionals should stop prescribing and dispensing lorcaserin to patients. Lorcaserin is a prescription medicine approved by fda in 2012 for use with a reducedcalorie diet and increased physical activity to help weight loss in adults who are obese or are overweight and. When fda approved lorcaserin in 2012, we required the drug manufacturer to conduct a randomized, doubleblind, placebocontrolled clinical trial to evaluate the risk of cardiovascular problems. Lorcaserin dosage does not depend on the age and sex of patients. Analyzing the results of clinical trials, ema paid attention to the fact that longterm use of lorcaserin increases the risk of developing mental. Productspecific guidances for generic drug development. Lorcaserin approved by fda pharmacology and physical therapy. Belviq lorcaserin hydrochloride tablets, for oral use initial u. Belviq is a serotonin 2c receptor agonist indicated as an adjunct to a reduced calorie. Based on initial clinical studies leading to its approval, lorcaserin is well tolerated and probably does not cause. Call your healthcare provider for medical advice about side effects.
Persistent concerns about lorcaserin lorqess from fda. Arena pharmaceuticals submits new drug application to fda. This draft guidance, when finalized, will represent the current thinking of the food and drug. This new drug application provides for the use of belviq xr. Fda issues complete response letter for lorcaserin new. The fda approved lorcaserin belviq lorcaserin hcl buy. About lorcaserin lorcaserin is an investigational new chemical entity that is believed to act as a selective serotonin 2c receptor agonist. Lorcaserin, which will be sold as belviq, received fda approval today, making it the first diet pill the government agency has approved in more than a decade. Lorcaserin is extensively metabolized in the liver by multiple enzymatic pathways. Should the fda approval process for weightloss drugs be.
Draft guidance on lorcaserin hydrochloride recommended may 2017 this draft guidance, when finalized, will represent the current thinking of the food and drug administration fda, or the agency on this topic. Lorcaserin belviq national drug monograph pharmacy benefits. Belviq is a serotonin 2c receptor agonist indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight. Arenas most advanced drug candidate, lorcaserin, is intended for weight management and has completed a pivotal phase 3 clinical trial program.
Lorcaserin is a serotonin receptor agonist, at the 5ht 2c and 5ht 2a receptor subtypes. Draft guidance on lorcaserin hydrochloride recommended mar 2015 this draft guidance, once finalized, will represent the food and drug administration s fda s current thinking on this topic. Guidance documents represent fda s current thinking on a topic. Cardiovascular safety of lorcaserin in overweight or obese.
Weightloss drug belviq recalled harvard health blog. It was removed from the market in the united states in 2020 due to its increased risk of cancer. Unlike to the food and drug administration fda approved lorcaserin as an obesity treatment, european medicines agency ema believes that lorcaserin advantages do not exceed it potential risks. These discrepancies will be corrected as soon as possible. Department of health and human services silver spring md 20993. Accordingly, your requirements under prea are as follows. Fda pregnancy category x in two pivotal clinical trials submitted to fda that excluded patients with diabetes, lorcaserin resulted in a mean percentage of body change in body weight of 5. Lorcaserin intra venous cocaine effects full text view.
In such cases, the name on the document correctly identifies the title of the guidance. The proportion of patients losing 5% of body weight with lorcaserin was 47%. Nda 022529 for belviq lorcaserin hydrochloride tablets, 10 mg, dated june 27, 2012, also apply to nda 208524 for belviq xr lorcaserin hydrochloride extended release tablets, 20 mg. For more information, see fda drug safety communication. Belviq xr lorcaserin hydrochloride extendedrelease tablets for oral use, civ. Lorcaserin is effective for weight loss in obese patients with and without type 2 diabetes, although its specific role in the management of obesity is unclear at this time. Fda advisory panel recommends approval for weight loss. Portable document format specifications food and drug. It is an important step for arena and eisai toward the fda s approval of lorcaserin. Belviq xr is a serotonin 2c receptor agonist indicated as an adjunct. Lorcaserin was previously shown to be efficacious for weight loss, which led to approval by the fda for longterm weight management in obese or overweight patients who had at least one weight.
Arena submitted the original nda for lorcaserin in december 2009, and the fda issued a complete response letter crl in october 2010. Inactive ingredients include silicified microcrystalline. Food and drug administration fda requested that the manufacturer of belviq. Arena will meet with the fda to obtain further clarity on the approval path and timeline. Learn more about lorcaserin in the midst of controversy over the weight loss drug qnexa, a new drug has entered the arena of consideration after it was approved by an fda advisory panel on thursday. Lorcaserin is a novel and selective agonist of the 5ht.
This draft guidance, once finalized, will represent the food and drug administrations fdas current thinking on this topic. Lorcaserin, marketed under the brand name belviq is a weightloss drug developed by arena pharmaceuticals. Lorcaserin is a serotonin 5ht agonist, fda approved in 2012 for longterm up to 2. Fda is alerting the public that results from a clinical trial assessing safety show a possible increased risk of cancer with the weight management medicine belviq, belviq xr lorcaserin. Sexspecific differences in lorcaserin exposure were observed in rats, with drug levels in plasma higher in females than in males see arena briefing doc, fda adcom 2010. Safety clinical trial shows possible increased risk of. Fda probing potential cancer link with weight loss drug lorcaserin. Arena submitted a response to the lorcaserin crl in december 2011. Draft guidance on lorcaserin hydrochloride food and drug.
It reduces appetite by activating a type of serotonin receptor known as the 5ht 2c receptor in a region of the brain called the hypothalamus, which is known to control appetite. Very few drugs are available for treatment of obesity, last drug approved by food and drug administration fda in 1999 was orlistat, after years a new prescription drug lorcaserin was approved in june 2012 by the fda. In july 2011, martin shkreli sent crew a powerpoint presentation on arena arna pharmaceuticals weight lossdrug lorcaserin that he had also sent to the fda in september 2010. Fda requests the withdrawal of the weightloss drug belviq. Federal register schedules of controlled substances.
It is used with diet and exercise in overweight adults with a weightrelated medical problem or obese adults to lose weight and keep it off lorcaserin is a serotonin 2c 5ht2c receptor agonist. Lorcaserin, combined with diet and exercise, can be used to produce. Arenas wholly owned subsidiary, arena pharmaceuticals gmbh, has granted eisai inc. Aap issues updated guidance on palivizumab prophylaxis for rsv infection. Those, who want to get rid of obesity by means of lorcaserin, should keep in mind that they could buy these weight loss tablets by prescription only. Lorcaserin hcl is a 5hydroxytryptamine 5ht 2c agonist with a chemical formula of r8chloro1methyl2,3,4,5tetrahydro1h3benzazepine hydrochloride hemihydrate.
It acts selectively at this receptor subtype with minimal activation of 5htr or 5htr receptors. Arena submitted a response to the lorcaserin crl in december. The fda is investigating a possible link between the prescription weight loss medication lorcaserin marketed as belviq, belviq xr and cancer. Fda requests lorcaserin be withdrawn from the market owing to a potential risk of cancer. Belviq is a serotonin 2c receptor agonist indicated as an adjunct to a reducedcalorie.
Panel advises fda to approve lorcaserin obesity pill cbs. Belviq xr lorcaserin hydrochloride extendedrelease tablets. Lorcaserin can decrease the metabolism of cyp2d6 substrates in one small trial of cyp2d6 extensive metabolizers, lorcaserin increased dextromethorphan peak concentrations by approximately 76%. They do not create or confer any rights for or on any person and do not operate to bind fda or the public. Although the exact mechanism of action is not known, lorcaserin is thought to selectively stimulate 5ht2c receptors in the. Call your doctor for medical advice about side effects. Fda accepts resubmission of lorcaserin new drug application.
1030 106 356 139 873 1242 1360 690 319 837 531 1479 885 1344 784 931 1479 560 150 1061 763 1000 540 1191 902 1222 171 270 1425 769 1231 1488 747 506 1111 1447 217 1140 704